{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.42","value":"74.1"},{"groupId":"OG001","spread":"21.85","value":"70.3"},{"groupId":"OG002","spread":"20.60","value":"77.1"},{"groupId":"OG003","spread":"18.58","value":"79.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"216"},{"groupId":"OG002","value":"59"},{"groupId":"OG003","value":"60"}],"units":"Participants"}],"title":"Expectations with Therapy, Week 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.58","value":"76.3"},{"groupId":"OG001","spread":"19.46","value":"74.0"},{"groupId":"OG002","spread":"17.88","value":"82.2"},{"groupId":"OG003","spread":"17.95","value":"82.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"210"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"55"}],"units":"Participants"}],"title":"Expectations with Therapy, Week 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.22","value":"74.5"},{"groupId":"OG001","spread":"20.96","value":"69.1"},{"groupId":"OG002","spread":"19.89","value":"73.3"},{"groupId":"OG003","spread":"17.46","value":"72.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"216"},{"groupId":"OG002","value":"59"},{"groupId":"OG003","value":"60"}],"units":"Participants"}],"title":"Feelings about Side-Effects, Week 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.83","value":"74.6"},{"groupId":"OG001","spread":"20.73","value":"69.9"},{"groupId":"OG002","spread":"24.46","value":"69.0"},{"groupId":"OG003","spread":"20.99","value":"69.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"210"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"55"}],"units":"Participants"}],"title":"Feelings about Side-Effects, Week 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.88","value":"84.4"},{"groupId":"OG001","spread":"13.60","value":"82.6"},{"groupId":"OG002","spread":"12.14","value":"87.2"},{"groupId":"OG003","spread":"11.07","value":"86.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"216"},{"groupId":"OG002","value":"59"},{"groupId":"OG003","value":"60"}],"units":"Participants"}],"title":"Satisfaction with Therapy, Week 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.94","value":"84.2"},{"groupId":"OG001","spread":"12.38","value":"84.6"},{"groupId":"OG002","spread":"13.29","value":"87.4"},{"groupId":"OG003","spread":"12.06","value":"87.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"210"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"55"}],"units":"Participants"}],"title":"Satisfaction with Therapy, Week 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"277"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"65"}],"units":"Participants"}],"description":"The CTSQ-16 was a 16-item questionnaire measuring 3 domains related to participant's satisfaction with cancer therapy: Expectations of therapy, Feelings about side effects, and Satisfaction with therapy. Scores ranged from 0 to 100 for each domain, with a higher score associated with the best outcome on each domain. The three domains of interest were separately analysed using an ANCOVA stratified by race (Asian versus Non-Asian) and mutation type (Ex19del versus L858R). The results of the analyses were presented in terms of mean together with standard deviation.","dispersionType":"Standard Deviation","groups":[{"description":"Randomized participants received Osimertinib 80 mg orally once daily (QD)","id":"OG000","title":"Osimertinib 80 mg (Global Cohort)"},{"description":"Randomized participant received Standard of care (SoC) Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Participants received gefitinib 250 mg orally QD or erlotinib 150 mg orally QD.","id":"OG001","title":"SoC EGFR-TKI (Global Cohort)"},{"description":"Randomized participants received Osimertinib 80 mg orally once daily (QD)","id":"OG002","title":"Osimertinib 80 mg (China Cohort)"},{"description":"Randomized participant received Standard of care (SoC) Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFRTKI). Participants received gefitinib 250 mg orally QD or erlotinib 150 mg orally QD.","id":"OG003","title":"SoC EGFR-TKI (China Cohort)"}],"paramType":"MEAN","populationDescription":"The full analysis set (FAS) and China-only FAS. FAS included all randomized participants prior to the end of global recruitment. The China-only FAS included all China participants randomized in mainland-China as part of the global study and all additional China participants recruited in mainland China after global recruitment was completed.","reportingStatus":"POSTED","timeFrame":"Questionnaire completed in cycle 2 and 3, prior to Week 6 scan (approximately 2 months)","title":"Participants Reported Outcome by Cancer Therapy Satisfaction Questionnaire 16 Items (CTSQ-16 Questionnaire)","type":"SECONDARY","unitOfMeasure":"Unit on scale"}